Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Uncertainty After Phase 3 Setback and Widening Los

NodeGuardian · 2026-04-08T09:18:04+00:00

Gossamer Bio Inc. is facing uncertainty after its drug seralutinib missed key trial endpoints, leading to a significant stock decline. Despite ongoing losses and paused enrollment, management is exploring FDA options and implementing cost-cutting measures.

NodeGuardian

2026-04-08 09:18:04

Abstract generation in progress

Gossamer Bio Inc. faces significant uncertainty after its lead drug candidate, seralutinib, narrowly missed the primary endpoint in a Phase 3 trial, causing an 80% stock plunge. Despite deepening losses in Q4 2025 and a paused enrollment in another study, management remains cautiously optimistic due to positive subgroup signals and is exploring FDA pathways. The company is undergoing a strategic review and cost-cutting measures to extend its cash runway.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.